What happened
CTC BIO reported consolidated results for FY2025: revenue of US$86M (−14.3% year on year), operating profit of US$4.34M (from a loss a year earlier) and net income of US$2.25M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$86M |
|---|---|
| Revenue vs a year earlier | −14.3% |
| Operating profit | US$4.34M |
| Net income | US$2.25M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-25, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260225901325 → open original filing |
Source: DART. Information only, not investment advice.